利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

58 条记录 (耗时 0.052 秒)

    Agents for preventing and treating disorders involving modulation of the ryanodine receptors
    2.
    发明授权
    Agents for preventing and treating disorders involving modulation of the ryanodine receptors 有权
    用于预防和治疗涉及调节兰诺定受体的疾病的药剂

    公开(公告)号：US08710045B2

    公开(公告)日：2014-04-29

    申请号：US12938098

    申请日：2010-11-02

    申请人： Andrew Robert Marks ,  Donald W. Landry ,  Shixian Deng

    发明人： Andrew Robert Marks ,  Donald W. Landry ,  Shixian Deng

    IPC分类号： A61P9/00 ,  A61K31/553 ,  A61K31/554 ,  C07D281/02

    CPC分类号： C07D281/10 ,  C07D417/12 ,  C07D417/14

    摘要： The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.

    摘要翻译： 本发明提供式I化合物及其盐，水合物，溶剂合物，络合物和前药。 本发明还提供了合成式I化合物的方法。本发明另外提供包含式I化合物的药物组合物和使用式I药物组合物的方法，以治疗和预防与调节钙的RyR受体相关的疾病和疾病 通道在单元格中起作用。

    NEURONAL PAIN PATHWAY
    4.
    发明申请
    NEURONAL PAIN PATHWAY 有权
    神经痛痛途径

    公开(公告)号：US20120295853A1

    公开(公告)日：2012-11-22

    申请号：US13569510

    申请日：2012-08-08

    申请人： Richard Ambron ,  Ying-Ju Sung ,  Donald W. Landry ,  Shi-Xian Deng

    发明人： Richard Ambron ,  Ying-Ju Sung ,  Donald W. Landry ,  Shi-Xian Deng

    IPC分类号： A61K31/55 ,  A61P25/00 ,  A61P25/04 ,  A61K38/02

    CPC分类号： A61K38/06 ,  A61K9/0014 ,  A61K9/7023 ,  A61K31/352 ,  A61K31/4422 ,  A61K31/55 ,  A61K38/02 ,  A61K38/07 ,  A61K38/465 ,  A61K47/64 ,  C12N9/1205 ,  C12Y301/04017

    摘要： The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

    摘要翻译： 本发明涉及发现涉及感觉神经元的长期兴奋性的新型分子途径，其在高等动物中与持续性疼痛相关。 基于这样的发现，在神经元轴突损伤之后，一氧化氮合酶活性的增加导致一氧化氮产生增加，这反过来激活鸟苷酸环化酶，从而增加cGMP的水平。 增加的cGMP导致蛋白激酶G（PKG）的激活，其然后沿着轴突逆行转运到神经元细胞体，其中磷酸化MAPKerk。

    Anti-cocaine catalytic antibody
    8.
    发明授权
    Anti-cocaine catalytic antibody 失效
    抗可卡因催化抗体

    公开(公告)号：US06280987B1

    公开(公告)日：2001-08-28

    申请号：US09214095

    申请日：1999-07-19

    申请人： Donald W. Landry

    发明人： Donald W. Landry

    IPC分类号： C12N900

    CPC分类号： C12N9/0002 ,  A61K38/00

    摘要： This invention provides a polypeptide comprising a light chain domain which comprises a complementarity determining region 1 having the amino acid sequence RSSXGTITXXNYAN (Seq ID No: 73), a complementarity determining region 2 having the amino acid sequence XNNYRPP (Seq ID No: 74) and a complementarity determining region 3 having the amino acid sequence ALWYSNHWV (Seq ID No: 75), interposed between appropriate framework regions, and linked to said light chain domain a heavy chain domain which comprises a complementarity determining region 1 having the amino acid sequence DYNMY (Seq ID No: 76), a complementarity determining region 2 having the amino acid sequence YIDPXNGXIFYNQKFXG (Seq ID No: 77) and a complementarity determining region 3 having the amino acid sequence GGGLFAX (Seq ID No: 78) interposed between appropriate framework regions, said polypeptide having a conformation suitable for degrading cocaine.

    摘要翻译： 本发明提供了包含轻链结构域的多肽，其包含具有氨基酸序列RSSXGTITXXNYAN（Seq ID No：73）的互补决定区域1，具有氨基酸序列XNNYRPP（Seq ID No：74）的互补决定区域2和 具有氨基酸序列ALWYSNHWV（Seq ID No：75）的互补决定区3，插入在适当的框架区之间，并连接到所述轻链结构域，重链结构域包含具有氨基酸序列DYNMY的互补决定区1（ Seq ID No：76），具有氨基酸序列YIDPXNGXIFYNQKFXG（Seq ID No：77）的互补决定区域2和插入适当框架区域之间具有氨基酸序列GGGLFAX（Seq ID No：78）的互补决定区域3， 所述多肽具有适于降解可卡因的构象。